Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | NQO2 | P16083 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 7/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16502432 | 0.90 | MAPT (0.48) | TP53ALDH1A1KMT2ASLC6A3NQO2 | |
| SCHEMBL7919793 | 0.88 | LCK (0.48) | TP53ALDH1A1KMT2ANQO2LCK | |
| SCHEMBL7921781 | 0.88 | TP53 (0.46) | TP53ALDH1A1KMT2ANQO2LCK | |
| SCHEMBL16502488 | 0.88 | TP53 (0.47) | TP53ALDH1A1KMT2ANQO2LCK | |
| SCHEMBL16502539 | 0.87 | NPC1 (0.45) | TP53ALDH1A1KMT2ANQO2LCK | |
| SCHEMBL16502581 | 0.84 | ALDH1A1 (0.53) | TP53ALDH1A1KMT2ASLC6A3NQO2 | |
| SCHEMBL16502527 | 0.84 | MAPT (0.47) | TP53ALDH1A1KMT2ASLC6A3NQO2 | |
| SCHEMBL7908929 | 0.84 | PLAU (0.48) | TP53ALDH1A1KMT2ANQO2LCK | |
| SCHEMBL16502742 | 0.84 | ALOX15 (0.46) | TP53ALDH1A1NQO2LCKMAPT | |
| SCHEMBL7917291 | 0.84 | TP53 (0.43) | TP53ALDH1A1KMT2ANQO2LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110306621-A1 | ACYLGUANIDINE DERIVATIVES | ASTELLAS PHARMA INC. (JP) | 2011-12-15 | — | — | US | disclosed |
| US-20110306621-A1 | ACYLGUANIDINE DERIVATIVES | ASTELLAS PHARMA INC. (JP) | 2011-12-15 | — | — | US | disclosed |
| WO-2010090304-A1 | ACYLGUANIDINE DERIVATIVE | アステラス製薬株式会社 (JP) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306621-A1 | ACYLGUANIDINE DERIVATIVES | HTR5A, HTR2A, HTR1A | TP53 2800/4885ALDH1A1 789/4885KMT2A 2627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.